5:19 PM
 | 
May 07, 2013
 |  BC Extra  |  Clinical News

Baxter's Gammagard fails in Phase III AD trial

Baxter International Inc. (NYSE:BAX) said both 200 and 400 mg/kg doses of IV Gammagard Liquid 10% given every two weeks missed the co-primary endpoints in the 390-patient Phase III GAP trial (Study 160701) to treat mild to moderate Alzheimer's disease (AD). Both low- and high-dose Gammagard did not reduce functional decline as measured by...

Read the full 256 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >